Pharmaceutical Research Initiatives
Pharmaceutical Research Initiatives
Strengthening new drug research and development capabilities in response to the diversification of modalities
Strengthening new drug research and development capabilities in response to the diversification of modalities
Leading the research and development of next-generation VHH antibodies
Promoting research to quickly bring pipeline drugs to market
Leading the research and development of next-generation VHH antibodies
Promoting research to quickly bring pipeline drugs to market
New drug development is becoming increasingly complicated around the world. In the future, without the development and continuous marketing of highly original new drugs, survival as a research and development-oriented company is likely to become more and more difficult. The new challenge facing Taisho Pharmaceutical is to develop extremely useful new drugs based on next-generation VHH antibodies. To achieve this, we are strengthening our research and development capabilities through means such as the use of advanced technologies and increased collaboration with outside research institutions.
In addition to drug discovery research, ensuring that pipeline drugs reach the market is also an important part of pharmaceutical research. We are continuously engaged in research and development activities, to give patients battling diseases access to the drugs they need as quickly as possible.
New drug development is becoming increasingly complicated around the world. In the future, without the development and continuous marketing of highly original new drugs, survival as a research and development-oriented company is likely to become more and more difficult. The new challenge facing Taisho Pharmaceutical is to develop extremely useful new drugs based on next-generation VHH antibodies. To achieve this, we are strengthening our research and development capabilities through means such as the use of advanced technologies and increased collaboration with outside research institutions.
In addition to drug discovery research, ensuring that pipeline drugs reach the market is also an important part of pharmaceutical research. We are continuously engaged in research and development activities, to give patients battling diseases access to the drugs they need as quickly as possible.
Initiatives for pharmaceutical research
Initiatives for pharmaceutical research
Next-generation VHH antibodies Taisho Pharmaceutical focuses on
Next-generation VHH antibodies Taisho Pharmaceutical focuses on
The next-generation VHH antibodies which Taisho Pharmaceutical is focusing on is the variable domain of camel heavy-chain antibodies (HCAb) where antigen binding occurs.
Because VHH antibodies are approximately a tenth the size of conventional antibodies, they have the potential to reach disease targets in the human body that are inaccessible to conventional antibodies.
The small, simple architecture also allows the creation of "multivalent" VHH compounds that can engage multiple targets at the same time by linking the individual VHHs together.
Leveraging the properties of VHHs, Taisho Pharmaceutical is focusing on the research and development of new drugs to follow in the footsteps of Nanozora, which is Japan's first next-generation VHH antibody for the treatment of rheumatoid arthritis.
The next-generation VHH antibodies which Taisho Pharmaceutical is focusing on is the variable domain of camel heavy-chain antibodies (HCAb) where antigen binding occurs.
Because VHH antibodies are approximately a tenth the size of conventional antibodies, they have the potential to reach disease targets in the human body that are inaccessible to conventional antibodies.
The small, simple architecture also allows the creation of "multivalent" VHH compounds that can engage multiple targets at the same time by linking the individual VHHs together.
Leveraging the properties of VHHs, Taisho Pharmaceutical is focusing on the research and development of new drugs to follow in the footsteps of Nanozora, which is Japan's first next-generation VHH antibody for the treatment of rheumatoid arthritis.
HCAb（heavy chain antibody）
VHH（variable domain of heavy chain of heavy chain antibody）
IgG (Immunoglobulin G)
HCAb（heavy chain antibody）
VHH（variable domain of heavy chain of heavy chain antibody）
IgG (Immunoglobulin G)
At Taisho Pharmaceutical, many researchers are involved at every stage of the drug development process, from proposing new drug discovery ideas, conducting research and development, and filing applications for approval, and they are constantly engaged in research and development activities to give patients battling diseases access to the drugs they need as quickly as possible. At the same time, Taisho Pharmaceutical is also building the base of technologies it needs to pursue research into next-generation VHH antibodies and is pushing ahead with research and development activities for new drug creation.
We are looking for likeminded colleagues who will join us in our new drug development activities.
At Taisho Pharmaceutical, many researchers are involved at every stage of the drug development process, from proposing new drug discovery ideas, conducting research and development, and filing applications for approval, and they are constantly engaged in research and development activities to give patients battling diseases access to the drugs they need as quickly as possible. At the same time, Taisho Pharmaceutical is also building the base of technologies it needs to pursue research into next-generation VHH antibodies and is pushing ahead with research and development activities for new drug creation.
We are looking for likeminded colleagues who will join us in our new drug development activities.
Pipeline
Pipeline
(As of May 12, 2025)
(As of May 12, 2025)
＊TS-142：Generic name: Bornolexant hydrate
＊＊TS-071: SGLT2 inhibitor Product name: Lusefi®
＊TS-142：Generic name: Bornolexant hydrate
＊＊TS-071: SGLT2 inhibitor Product name: Lusefi®
